IDXX vs. IMMU, LNTH, QDEL, NEOG, CLDX, ISRG, SYK, BSX, MDT, and BDX
Should you be buying IDEXX Laboratories stock or one of its competitors? The main competitors of IDEXX Laboratories include Immunomedics (IMMU), Lantheus (LNTH), QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), and Becton, Dickinson and Company (BDX). These companies are all part of the "medical" sector.
Immunomedics (NASDAQ:IMMU) and IDEXX Laboratories (NASDAQ:IDXX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability.
Immunomedics has a beta of 2.9, indicating that its share price is 190% more volatile than the S&P 500. Comparatively, IDEXX Laboratories has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.
IDEXX Laboratories has a net margin of 23.26% compared to IDEXX Laboratories' net margin of 0.00%. Immunomedics' return on equity of 63.66% beat IDEXX Laboratories' return on equity.
In the previous week, IDEXX Laboratories had 8 more articles in the media than Immunomedics. MarketBeat recorded 8 mentions for IDEXX Laboratories and 0 mentions for Immunomedics. Immunomedics' average media sentiment score of 1.26 beat IDEXX Laboratories' score of 0.00 indicating that IDEXX Laboratories is being referred to more favorably in the news media.
IDEXX Laboratories received 86 more outperform votes than Immunomedics when rated by MarketBeat users. Likewise, 72.69% of users gave IDEXX Laboratories an outperform vote while only 65.24% of users gave Immunomedics an outperform vote.
88.9% of Immunomedics shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 12.0% of Immunomedics shares are held by company insiders. Comparatively, 2.1% of IDEXX Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
IDEXX Laboratories has a consensus target price of $580.38, indicating a potential upside of 16.79%. Given Immunomedics' higher possible upside, analysts clearly believe IDEXX Laboratories is more favorable than Immunomedics.
IDEXX Laboratories has higher revenue and earnings than Immunomedics. Immunomedics is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
IDEXX Laboratories beats Immunomedics on 13 of the 17 factors compared between the two stocks.
Get IDEXX Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for IDXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IDXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IDEXX Laboratories Competitors List
Related Companies and Tools
